Fulvestrant with or without AZD6244, a mitogen-activated protein kinase kinase (MEK) ½ inhibitor, in advanced stage breast cancer progressing after aromatase inhibitor: A randomized placebo-controlled double-blind phase II trial

Project

Fulvestrant with or without AZD6244, a mitogen-activated protein kinase kinase (MEK) ½ inhibitor, in advanced stage breast cancer progressing after aromatase inhibitor: A randomized placebo-controlled double-blind phase II trial

Completed · 2010 until 2012

Hasler-Strub Ursula, Ruhstaller Thomas, Huober Jens, Mark Michael

Type

Clinical Studies

Range

Multicentric, KSSG as participating partner

Units

Medizinische Onkologie und Hämatologie, Brustzentrum St.Gallen

Status

Completed

Start Date

2010

End Date

2012

Financing

Others

Study Design

Phase II

Keywords

Fulvestrant, AZD6244, MEK, 1/2 inhibitor, advanced stage breast cancer, aromatase inhibitor

Homepage

http://-

Partner

Additional Information

Brief description/objective

Einige Krebszellen sind resistent gegenüber klassischer Hormontherapie. AZD6244 ist eine Substanz, welche einen der wichtigsten Resistenzmechanismen blockieren kann.